About CoreTissue BioEngineering
CoreTissue BioEngineering is a company based in Yokohama (Japan) founded in 2016. CoreTissue BioEngineering has raised $3.91 million across 1 funding round from investors including NH Foods. CoreTissue BioEngineering operates in a competitive market with competitors including Moximed, Allay Therapeutics, Abanza Tecnomed, Sparta Biomedical and Jointmedica, among others.
- Headquarter Yokohama, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.91 M (USD)
in 1 rounds
-
Latest Funding Round
$3.91 M (USD), Series A
Nov 10, 2025
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CoreTissue BioEngineering
CoreTissue BioEngineering has successfully raised a total of $3.91M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.91 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CoreTissue BioEngineering
CoreTissue BioEngineering has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NH Foods.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Meat and meat products are produced by NH Foods.
|
Locked | Locked | Locked |
Investor details for CoreTissue BioEngineering
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CoreTissue BioEngineering
Investment portfolio details for CoreTissue BioEngineering
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CoreTissue BioEngineering
Detailed financials for CoreTissue BioEngineering
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coretissue Bioengineering Comparisons
Peer comparison for CoreTissue BioEngineering
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CoreTissue BioEngineering
CoreTissue BioEngineering operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moximed, Allay Therapeutics, Abanza Tecnomed, Sparta Biomedical and Jointmedica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A knee implant for pre-arthroplasty osteoarthritis patients is developed.
|
|
| Locked | Locked | Locked |
Post-surgical pain drugs are developed using non-opioid biopolymer technology.
|
|
| Locked | Locked | Locked |
Surgical instruments for sports medicine procedures are developed.
|
|
| Locked | Locked | Locked |
Synthetic cartilage platforms are developed for orthopedic surgeons.
|
|
| Locked | Locked | Locked |
Smart knee replacement devices matching natural anatomy are provided.
|
Detailed competitors of CoreTissue BioEngineering
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coretissue Bioengineering
Complete news archive for CoreTissue BioEngineering
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CoreTissue BioEngineering
CoreTissue BioEngineering was founded in 2016 and raised its 1st funding round 9 years after it was founded.
CoreTissue BioEngineering is headquartered in Yokohama, Japan. It is registered at Yokohama, Kanagawa, Japan.
Yoji Shirokura is the current CEO of CoreTissue BioEngineering.
CoreTissue BioEngineering is a funded company, having raised a total of $3.91M across 1 funding round to date.
CoreTissue BioEngineering was founded in 2016 in Yokohama, Japan, within the bioengineering sector. Implantable medical devices are developed using living tissues, with a focus on artificial ligaments for anterior cruciate ligament reconstruction in the knee. Decellularized animal tissues are employed, where cellular components are removed prior to transplantation into the human body. Operations center on tissue processing and device integration for orthopedic applications.
CoreTissue BioEngineering's top competitors include Moximed, Allay Therapeutics and Sparta Biomedical.
CoreTissue BioEngineering has 1 investor. Key investors include NH Foods.